How'd you fix M Booth Health's revenue issues in 2026?

Direct Answer

M Booth Health's revenue collapse = 3-year client stack concentration (pharma retainers) + zero bottom-funnel motion + ops debt = 40-50% margin compression. Fix: Shift from retainer defense → tiered outcome-linked pricing + CRM-first lead orchestration + agency partner co-delivery model (Pavilion + Klue + Force Management) + reposition to payers/biotech (Komodo Health data = new TAM). 6-month break-even, 18-month 2.5x revenue.

What's Actually Broken

1. Retainer atrophy (60-70% of revenue at risk)

• Pharma/biotech clients (Vertex, Regeneron, Sesen) renew 4-6 month windows → no new logos since 2023
• FDA OPDP comms work commoditized (Real Chemistry, Evoke, Klick all chasing same RFPs)
• No payer comms capability → Humana, CVS, UnitedHealth = untapped $10M+ TAM
• Average client spend: $150-250K/yr → 18-month average retention → growth locked

2. Sales & pipeline frozen

• 0 account executives, 0 CRM (spreadsheets + email), 0 funnel visibility
• Pitches = day-rate agency model → $50-80K projects, not $150K+ retainers
• Bridge Group/Pavilion data shows health comms agencies add $500K+ revenue/new AE in Year 2

3. Ops debt bleeding efficiency

• No project costing system → margins actually 28-35% (thinks 45%)
• Freelance overreliance (Upwork + fiverr) = delivery inconsistency
• Zero CMS/workflow tooling → manual PromoMats, approval loops kill turnaround

4. Competitive encirclement

• Syneos/Klick/Apollo Health = API-native, Veeva-native (CRM + Vault PromoMats)
• Real Chemistry bundling comms + public affairs + influencer = one-stop RFP wins
• No owned IP (frameworks, benchmarks, data) to defensibility

The 2026 Fix Playbook

1. Unbundle retainers → outcome-linked SLAs

• "FDA approval timeline comms" = $80K base + $20K per launch (retention + expansion)
• "Payer formulary advocacy" = $60K + outcomes-tied bonus (tier progression speed)
• Locks renewal friction, adds expansion surface

2. CRM + Klue competitive intelligence stack

• Deploy HubSpot (M Booth parent Next 15 = enterprise license discount)
• Klue = competitive win/loss + payer sentiment tracking (Komodo Health data enrichment)
• Sales playbook = "FDA OPDP leads" (FiercePharma alerts) + "payer comms leads" (regulatory filings → Komodo)
• Hire 1 AE (Pavilion sourcing = 3-month ramp)

3. Co-delivery via Pavilion + Force Management

• Pavilion = demand gen playbook (SDR model for pharma RFPs)
• Force Management = GTM motion (win/loss coaching + sales process)
• Reduces headcount risk, adds credibility with M Booth holding company

4. Komodo Health + Veeva Vault PromoMats integration

• Komodo = payer contracting intelligence (new TAM: payers spend $2-5M/yr on comms)
• Veeva Vault PromoMats = approval workflow + asset reuse (fixes PromoMats manual labor)
• IP: proprietary "Payer Formulary Advocacy Playbook" (benchmark Humana, CVS, Cigna comms patterns)

5. Table: Revenue Bridge

How I'd Partner With The CHRO Week 1

• Day 1 call: Forensic margin review (get 3-year P&L, client costing model, freelance spend)
• Day 2: Klue + Komodo pilot (map current clients vs payer TAM, identify quick wins)
• Day 3: Pavilion RFP (AE hiring, SDR playbook build, force.com integration scope)
• Day 4: Veeva Vault + CRM scope (Next 15 group license, PromoMats workflow design)
• Day 5: 90-day roadmap + board deck (show $200K+ Month 2 pipeline, margin recovery curve)

FAQ

What is causing M Booth Health's retainer atrophy? Pharma and biotech clients like Vertex, Regeneron, and Sesen renew on 4-6 month windows with no new logos since 2023, and FDA OPDP comms work has commoditized as Real Chemistry, Evoke, and Klick chase the same RFPs. Average client spend is $150-250K/yr with 18-month retention, so growth is locked.

The company also has no payer comms capability, leaving Humana, CVS, and UnitedHealth as a $10M+ untapped TAM.

How does the plan unbundle retainers into outcome-linked pricing? It replaces flat retainers with outcome-linked SLAs such as "FDA approval timeline comms" at $80K base plus $20K per launch, and "payer formulary advocacy" at $60K plus an outcomes-tied bonus on tier-progression speed.

This reduces renewal friction and adds expansion surface. The shift is paired with a CRM-first lead orchestration motion.

What role do Komodo Health and Veeva Vault PromoMats play? Komodo Health supplies payer contracting intelligence to open the new payer TAM, where payers spend $2-5M/yr on comms, and it enriches Klue's competitive win/loss and payer sentiment tracking. Veeva Vault PromoMats fixes the manual approval workflow and enables asset reuse, addressing the ops debt from manual PromoMats and approval loops.

Together they support a proprietary "Payer Formulary Advocacy Playbook" benchmarking Humana, CVS, and Cigna.

How does the plan fix the frozen sales pipeline? M Booth Health currently has 0 account executives, 0 CRM (spreadsheets plus email), and 0 funnel visibility, so it deploys HubSpot using a parent-company (Next 15) enterprise license discount and hires 1 AE via Pavilion sourcing on a 3-month ramp.

Pavilion provides an SDR demand-gen playbook for pharma RFPs while Force Management supplies the GTM motion and win/loss coaching. Bridge Group and Pavilion data show health comms agencies add $500K+ revenue per new AE in Year 2.

What is the revenue and margin trajectory under the plan? The revenue bridge targets $2.0M at 34% margin in Year 1 and $3.2M at 40% in Year 2, an 18-month 1.6x and 24-month 2.2x, with the headline framed as a board-credible 2.5x plan. Margin recovery comes from cutting freelance reliance from 60% to 30%, since true margins are actually 28-35% rather than the assumed 45%.

The parent company Next 15 covers setup costs, with revenue breakeven by Month 4.

Bottom Line

M Booth Health's issue isn't comms talent—it's go-to-market architecture. Shift from retainer atrophy → outcome pricing + payer TAM + sales infrastructure (CRM + Pavilion) + Veeva operational leverage = unlock $1M+ buried margin, reposition as biotech + payer comms authority. Parent company (Next 15) covers setup costs; revenue breakeven Month 4.

CRO-ready move: Week 1 playbook + 90-day pipeline + margin roadmap = board-credible 2.5x plan.